Difference between revisions of "Part:BBa K3096015"
m |
(→Characterisation by iGEM Tuebingen 2019) |
||
Line 18: | Line 18: | ||
===Characterisation by iGEM Tuebingen 2019=== | ===Characterisation by iGEM Tuebingen 2019=== | ||
− | Team iGEM Tuebingen 2019 has added and characterised pVEC by building a software tool which | + | Team iGEM Tuebingen 2019 has added and characterised pVEC by building a software tool, '''C3Pred''', which predicts the penetrability of CPPs, comparing their activity. The results of the characterisation are shown in Fig. 1, where common or new CPPs are shown with their respective penetrability. |
===Biosafety=== | ===Biosafety=== |
Revision as of 07:03, 17 October 2019
pVEC - a cell penetrating peptide
pVEC (peptide vascular endothelial-cadherin) is a cell-penetrating peptide, which transports proteins through coadministration.
Contents
Biology & Usage
Through their penetrating activity, Cell penetrating peptides can be utilised as carriers of peptide- and protein-based pharmaceuticals across membranes, eg. Insulin across rat intestinal cells (Kamei et al.). This is highly relevant, since advances in biotechnology resulted in therapeutics, which can only be administered parenterally due to their minimal bioavailability (Kamei et al.). Since cytotoxic effects, induced by the disintegration of the plasma membrane, have occured, improvement and development of cell penetrating peptides is necessary.
Moreover, Kamei et al. propose that cell penetrating peptides gain their activity through the abundance of multiple positive charges (argine, R) and the ability to form an amphipathic helix.
pVEC is derived from a segment of the transmembrane domain part of a murine vascular endothelial-cadherin protein, which is involved in cell-cell adhesion (Elmquist et al.). Its ability to enter the cell can mostly be explained by the N-terminal stretch of hydrophobic amino acids, which interact with the plasma membrane and potentially induces endocytosis (Elmquist et al.). It was shown by Kamei et al., that the coadministration of pVEC with Insulin increases its intestinal uptake in rat cells, suggesting it a suitable tool for the oral delivery route of drugs.
Meanwhile, Elmquist et al. also showed that an incubation with 10µM pVEC for up to 1 hour at 37°C did not cause significant leakage (measured by lactate dehydrogenase in the extracellular space), indicating that pVEC does not confer to a strong cytotoxic effect. This is beneficial if the cell penetrating peptide is detined to be used in drug delivery.
Sequence and Features
pVEC consists of a stretch of 18 amino acids, with the N-terminal hydrophobic amino acids being crucial determinants of the uptake. We propose future iGEM Teams to improve this part by exchanging Arg6, Arg8 or Ser17 by alanine. According to Elmquist et al., this is supposed to increase the penetrating activity.
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Characterisation by iGEM Tuebingen 2019
Team iGEM Tuebingen 2019 has added and characterised pVEC by building a software tool, C3Pred, which predicts the penetrability of CPPs, comparing their activity. The results of the characterisation are shown in Fig. 1, where common or new CPPs are shown with their respective penetrability.
Biosafety
Together with professional safety officials, Team iGEM Tuebingen 2019 has evaluated the biosafety of cell penetrating peptides and has come to the conclusion that cell penetrating peptides are to be classified as BSL1.
References
- Kamei, Noriyasu, et al. "Usefulness of cell-penetrating peptides to improve intestinal insulin absorption." Journal of Controlled Release 132.1 (2008): 21-25.
- Elmquist, Anna, Mats Hansen, and Ülo Langel. "Structure–activity relationship study of the cell-penetrating peptide pVEC." Biochimica et Biophysica Acta (BBA)-Biomembranes 1758.6 (2006): 721-729.